ArticleKidney international2014
Molecular interactions of FGF23 and PTH in phosphate regulation.
Article in Kidney international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Oral vitamin DOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Pooled it
- Review
- Incidence, risk factors and survival outcomes of post-transplant tertiary hyperparathyroidism in kidney recipients.World journal of transplantation · 2026Article
- Mendelian randomization study of micronutrients and development of CKD in a Korean population.Nutrition journal · 2025Article
- Genetic deletion of the kidney sodium/proton exchanger-3 (NHE3) does not alter calcium and phosphate balance due to compensatory responses.Kidney international · 2025Article
- Risk factors for developing osteoporosis in diabetic kidney disease and its correlation with calcium-phosphorus metabolism, FGF23, and Klotho.World journal of diabetes · 2025Article
- Emerging concepts on the FGF23 regulation and activity.Molecular and cellular biochemistry · 2025Review
- Severe hypophosphataemia and hypocalcaemia following intravenous ferric derisomaltose and denosumab administration.BMJ case reports · 2024Article
- Circadian Regulation of Endocrine Fibroblast Growth Factors on Systemic Energy Metabolism.Molecular pharmacology · 2024Review
- The Role of the FGF19 Family in the Pathogenesis of Gestational Diabetes: A Narrative Review.International journal of molecular sciences · 2023Review
- Significance of changes in FGF23 levels in childhood primary nephrotic syndrome and children who progress to end‑stage renal disease.Experimental and therapeutic medicine · 2023Article
- Vitamin D and Chronic Kidney Disease Association with Mineral and Bone Disorder: An Appraisal of Tangled Guidelines.Nutrients · 2023Review
- Bioactive, full-length parathyroid hormone delivered using an adeno-associated viral vector.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Interactions between FGF23 and vitamin D.Endocrine connections · 2022Review
- Osteoprotegerin, Parathyroid Hormone and Vitamin D as Effective Factors on Serum-Urine Calcium Levels in Breast Cancer Patients.Archives of Razi Institute · 2022Article
- Effects of acid on bone.Kidney international · 2022Review
- A rare combination of tumor-induced osteomalacia caused by sinonasal glomangiopericytoma and coexisting parathyroid adenoma: case report and literature review.BMC endocrine disorders · 2022Review
- Beyond Bone: Infectious Diseases and Immunity in Parathyroid Disorders.Advances in experimental medicine and biology · 2022Article
- Environmental Factors That Affect Parathyroid Hormone and Calcitonin Levels.International journal of molecular sciences · 2021Review
- Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bone-derived fibroblast growth factor-23 (FGF23) plays an important role in systemic phosphate turnover. Increased FGF23 activity results in hypophosphatemic disorders, while reduced activity is linked to hyperphosphatemic disorders. FGF23, together with klotho as co-factor, can activate FGF receptors in its target tissues to exert its functions. However, the molecular regulation of FGF23 synthesis is not clearly defined, and recent studies have found that parathyroid hormone (PTH) can activate the nuclear receptor-associated protein-1 (Nurr1) to induce FGF23 transcription in bone cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.